SZABO SCANDIC

Part of Europa Biosite

Produktinformation

- Forschungsprodukte & Biochemikalien
- Zellkultur & Verbrauchsmaterial
- Diagnostik & molekulare Diagnostik
- Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!

Lieferung & Zahlungsart

siehe unsere Liefer- und Versandbedingungen

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

linkedin.com/company/szaboscandic

Keliximab

Cat. No.:	HY-P99680
CAS No.:	174722-30-6
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description

Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a K_i value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research[1] [2].

In Vitro

Keliximab shows a K_d value of 1.0 nM for binding with soluble CD4 (sCD4)[2].

Keliximab (0.01-10 μg/mL; 30 min) dose-dependently binds to the $CD4^+$ thymoma cell line SupT1 with an ED_{50} of 0.2 μg/mL [1].

Keliximab (0-1000 ng/mL) blocks T cell proliferation and IL-2 production with IC_{50}s of 10-30 ng/mL in primary human plasmablastic lymphomas (PBLs)[1].

Keliximab (1-1000 ng/mL; 5 min) dose-dependently mediates cell-cell adhesion with an ED_{50} value of 20 ng/mL[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Keliximab (5-125 mg/kg; i.v., once) decreases $CD4^+$ T cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Transgenic mice bearing human CD4 molecules on their T cells[1]
Dosage:	5-125 mg/kg
Administration:	Intravenous injection, 5-125 mg/kg, once
Result:	Dose-dependently down-modulated CD4 and rapidly declined the number of circulating $CD4^+$ T cells compared with clenoliximab.

REFERENCES

[1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.

[2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA